Catabasis Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.36 to $2.64 in the past one-month time frame.
The company has not seen any estimate revisions in the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Catabasis Pharmaceuticals currently has a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Another stock worth considering in the Medical - Biomedical and Genetics industry is Ligand Pharmaceuticals Incorporated , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is CATB going up? Or down? Predict to see what others think: Up or Down
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Image: Bigstock
Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher
Catabasis Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.36 to $2.64 in the past one-month time frame.
The company has not seen any estimate revisions in the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Catabasis Pharmaceuticals currently has a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Catabasis Pharmaceuticals, Inc. Price
Catabasis Pharmaceuticals, Inc. Price | Catabasis Pharmaceuticals, Inc. Quote
Another stock worth considering in the Medical - Biomedical and Genetics industry is Ligand Pharmaceuticals Incorporated , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is CATB going up? Or down? Predict to see what others think: Up or Down
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>